Back to Agenda
Understanding the Misconceptions and Myths around Surrogate Endpoints
Session Chair(s)
Bridget Doherty, MPH, MS
Director, Access and Policy Research
Johnson & Johnson, United States
Explore the science and debate surrounding the FDA’s use of surrogate endpoints in drug approvals, with a focus on their role in addressing unmet medical needs. This session will bring together diverse perspectives to clarify misconceptions.
Learning Objective : Provide an evidence-based overview of the development and utilization of surrogate endpoints in FDA approvals; Examine the increasing reliance on surrogates, particularly case studies in fields like rare diseases and oncology, where overall survival data may be years away; Incorporate the patient and provider perspective to understand what constitutes “meaningful” endpoints and how these may
Speaker(s)
Panelist
Representative Invited
FDA, United States
Have an account?